邁瑞醫療(300760.SZ)大漲超10% 果斷回購+北上資金加倉
格隆匯9月6日丨A股醫藥股集體走強,其中,邁瑞醫療(300760.SZ)大漲超10%至364.9元,股價創8月17日以來新高,市值逾4400億元。據格隆匯APP數據顯示,自8月以來至今,北上資金持續加倉邁瑞醫療,共計淨買入67.48億元。另外,邁瑞醫療近日果斷回購。8月24日董事會確定回購方案,擬使用自有資金10億元回購股份,用於實施股權激勵計劃或員工持股計劃,回購價格不超400元。截至9月1日,邁瑞醫療完成回購方案,累計回購304.87萬股,回購價格為316.18元/股至335元/股,花費資金近10億元(含交易費用)。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.